---
title: "Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286776980.md"
description: "Nanobiotix reported promising Phase 2 data for its nanoradioenhancer NBTXR3 in treating stage 3 inoperable lung cancer. The trial showed an 85.7% overall response rate and a 57.1% complete response rate, indicating potential for deeper responses compared to standard treatments. Analysts rate NBTX stock as a Buy with a $36.00 price target, though concerns about financial fundamentals persist. Nanobiotix focuses on developing nanotherapeutics for cancer treatment, with ongoing partnerships and clinical programs."
datetime: "2026-05-18T13:06:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286776980.md)
  - [en](https://longbridge.com/en/news/286776980.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286776980.md)
---

# Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Nanobiotix ( (NBTX) ) just unveiled an update.

On May 17, 2026, Nanobiotix reported that Johnson & Johnson presented Part 1 data from the CONVERGE randomized Phase 2 trial of its nanoradioenhancer JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer at the ESTRO 2026 meeting. Early results from seven patients showed that intratumoral or intranodal injection of JNJ-1900 combined with concurrent chemoradiotherapy and durvalumab was feasible and appeared safe, with an overall response rate of 85.7%, a complete response rate of 57.1%, a disease control rate of 100%, and no progressive disease observed.

These initial outcomes suggest deeper and potentially more durable responses than typically seen with current standard-of-care chemoradiation with or without durvalumab, where complete responses are usually below 5%. The data strengthen Nanobiotix’s strategic positioning around NBTXR3 as a potentially first-in-class, scalable radioenhancer across solid tumors, complementing its ongoing Phase 3 NANORAY-312 head and neck cancer program and its global co-development and commercialization alliance with Johnson & Johnson.

The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

**Spark’s Take on NBTX Stock**

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

The score is primarily constrained by weak financial fundamentals (ongoing losses, cash burn, and balance-sheet pressure including negative equity and higher leverage). Offsetting this are strong technical momentum (though extended) and a constructive earnings-call outlook emphasizing improved runway and multiple clinical catalysts, while valuation support is limited given negative earnings and no dividend.

To see Spark’s full report on NBTX stock, click here.

**More about Nanobiotix**

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and Nasdaq, developing physics-based nanotherapeutics to improve cancer treatment. Its lead product candidate, JNJ-1900 (NBTXR3), is a hafnium oxide nanoparticle radioenhancer designed for one-time intratumoral injection and activation by radiotherapy, with a development focus on solid tumors such as head and neck cancers and partnerships including Janssen and MD Anderson.

**Average Trading Volume:** 75,328

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $2.46B

For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [NBTX.US](https://longbridge.com/en/quote/NBTX.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study  | NBTX Stock News](https://longbridge.com/en/news/285126081.md)
- [FY2027 EPS Estimates for Nanobiotix Decreased by Analyst](https://longbridge.com/en/news/281917063.md)
- [Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference](https://longbridge.com/en/news/286726324.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)